{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:02:19Z","timestamp":1783702939743,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T00:00:00Z","timestamp":1693872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Akeso Biopharma Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s13555-023-01010-1","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T10:02:48Z","timestamp":1693908168000},"page":"2357-2373","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Safety, Pharmacokinetics and Preliminary Efficacy of IL4-R\u03b1 Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04256174","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christopher John","family":"Wynne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Cole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Lemech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benchao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"1010_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-3-319-64804-0_3","volume":"1027","author":"W David Boothe","year":"2017","unstructured":"David Boothe W, Tarbox JA, Tarbox MB. Atopic Dermatitis: Pathophysiology. Adv Exp Med Biol. 2017;1027:21\u201337. https:\/\/doi.org\/10.1007\/978-3-319-64804-0_3. (PMID: 29063428).","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"1010_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3390\/children10020273","volume":"10","author":"N Douladiris","year":"2023","unstructured":"Douladiris N, Vakirlis E, Vassilopoulou E. Atopic dermatitis and water: is there an optimum water intake level for improving atopic skin? Children (Basel). 2023;10(2):273. https:\/\/doi.org\/10.3390\/children10020273.","journal-title":"Children (Basel)"},{"issue":"2","key":"1010_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","volume":"40","author":"J Kim","year":"2019","unstructured":"Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40(2):84\u201392. https:\/\/doi.org\/10.2500\/aap.2019.40.4202.","journal-title":"Allergy Asthma Proc"},{"key":"1010_CR4","first-page":"2","volume":"1","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Barbarot S, Gadkari A, et al. Epidemiology of atopic dermatitis (AD) in children aged 6\u201311 years: a cross-sectional study in the United States (US), Canada, Europe, and Japan. Skin. 2020;1:2.","journal-title":"Skin"},{"issue":"6","key":"1010_CR5","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","volume":"124","author":"JA Odhiambo","year":"2009","unstructured":"Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124(6):1251-8.e23.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1010_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5021\/ad.2010.22.2.125","volume":"22","author":"T Bieber","year":"2010","unstructured":"Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22(2):125\u201337.","journal-title":"Ann Dermatol"},{"issue":"3","key":"1010_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137. https:\/\/doi.org\/10.1016\/j.anai.2018.07.006.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"1010_CR8","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","volume":"83","author":"AS Paller","year":"2020","unstructured":"Paller AS, Siegfried EC, Tha\u00e7i D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83(5):1282\u201393.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1010_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100604","volume":"14","author":"WL Dong","year":"2021","unstructured":"Dong WL, An J, Yu M, et al. The prevalence and year lived with disability of atopic dermatitis in China: Findings from the global burden of disease study 2019. World Allergy Organ J. 2021;14(11):100604.","journal-title":"World Allergy Organ J"},{"issue":"1","key":"1010_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","volume":"156","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(1):44\u201356.","journal-title":"JAMA Dermatol"},{"issue":"24","key":"1010_CR11","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"1010_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jaip.2020.11.034","volume":"9","author":"T Ratchataswan","year":"2021","unstructured":"Ratchataswan T, Banzon TM, Thyssen JP, Weidinger S, Guttman-Yassky E, Phipatanakul W. Biologics for treatment of atopic dermatitis: current status and future prospect. J Allergy Clin Immunol Pract. 2021;9(3):1053\u201365. https:\/\/doi.org\/10.1016\/j.jaip.2020.11.034.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"1010_CR13","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.pcl.2019.06.008","volume":"66","author":"S Saini","year":"2019","unstructured":"Saini S, Pansare M. New insights and treatments in atopic dermatitis. Pediatr Clin North Am. 2019;66(5):1021\u201333. https:\/\/doi.org\/10.1016\/j.pcl.2019.06.008.","journal-title":"Pediatr Clin North Am"},{"issue":"4S","key":"1010_CR14","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","volume":"139","author":"PM Brunner","year":"2017","unstructured":"Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65\u201376.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1010_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","volume":"13","author":"NA Gandhi","year":"2017","unstructured":"Gandhi NA, Pirozzi G, Graham N. Commonality of the IL-4\/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425\u201337.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"1010_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaci.2008.04.022","volume":"122","author":"KO Kisich","year":"2008","unstructured":"Kisich KO, Carspecken CW, Fi\u00e9ve S, Boguniewicz M, Leung DY. Defective killing of Staphylococcus aureus in atopic dermatitis is associated with reduced mobilization of human beta-defensin-3. J Allergy Clin Immunol. 2008;122(1):62\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1010_CR17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/cpdd.798","volume":"9","author":"Z Li","year":"2020","unstructured":"Li Z, Radin A, Li M, et al. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. Clin Pharmacol Drug Dev. 2020;9(6):742\u201355.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"1010_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA,  Tha\u00e7i D,  Hamilton JD et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. New Engl J Med. 2014;371(2):130\u20139.","journal-title":"New Engl J Med"},{"issue":"7","key":"1010_CR19","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/eji.200635972","volume":"36","author":"G Wirnsberger","year":"2006","unstructured":"Wirnsberger G, Hebenstreit D, Posselt G, Horejs-Hoeck J, Duschl A. IL-4 induces expression of TARC\/CCL17 via two STAT6 binding sites. Eur J Immunol. 2006;36(7):1882\u201391.","journal-title":"Eur J Immunol"},{"issue":"1","key":"1010_CR20","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1067\/mai.2000.106776","volume":"106","author":"K Izuhara","year":"2000","unstructured":"Izuhara K,\u00a0Yanagihara Y,\u00a0Hamasaki N,\u00a0Shirakawa T,\u00a0Hopkin JM. Atopy and the human IL-4 receptor \u03b1 chain. J Allergy Clin Immunol. 2000;106(1):S65\u201371.","journal-title":"J Allergy Clin Immunol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01010-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T15:07:50Z","timestamp":1695913670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01010-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1010"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01010-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"assertion":[{"value":"10 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was designed and conducted according to guidelines of Good Clinical Practice(GCP), the current Declaration of Helsinki and National Medical Product Administration (NMPA). The protocol of this study was approved by the ethics committee. An informed consent document approved by independent ethics committee was signed by the subjects or their legally authorized representative before the participant entered in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All named authors made substantial contributions to the conception or design of the work, or to the acquisition, analysis or interpretation of data. All named authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy of integrity of any part of the work are appropriately investigated and resolved and have given their approval for this version to be published. All named authors meet the international Committee of Medical Journal(ICMJE) criteria for authorship for this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship"}}]}}